Aralez Pharmaceuticals Inc. et al v. Teva Pharmaceuticals USA, Inc. et al, No. 2:17-cv-00071 (E.D. Tex. Aug. 10, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court is the Report and Recommendation filed by Magistrate Judge Payne on July 17, 2017 (Dkt. No. 64) recommending that Defendant Teva Pharmaceuticals USA, Inc.’s (“Defendant” or “Teva”) Motion to Dismiss for Improper Venue (Dkt. No. 38) be deni ed. Defendant Teva has filed an objection seeking reconsideration of the Report and Recommendation. (Dkt. No. 67.) The Court has reviewed the Report and Recommendation de novo and finds no reason to reject or modify the recommended disposition. See Fed. R. Civ. P. 72(b); Davidson v.